Video
VIDEO: Practice changers out of ASH 2017
ATLANTA – Dr. Robert Brodsky shares his takeaways on the key practice changing data presented in the ASH 2017 late breakers.
News
CLL drug in limited supply outside U.S.
Patients outside the United States will be able to access the drug only through compassionate use programs.
Audio
AUDIO: Immunotherapy’s role in NHL
Dr. Stephen Ansell outlines the challenges in using immunotherapy effectively in non-Hodgkin lymphoma and future directions.
News
FDA expands indication for bosutinib in newly diagnosed CML
The new indication includes treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome–positive CML.
News
Gene therapy regimen for XSCID shows rapid results in newly diagnosed infants
ATLANTA – The regimen combines a modified lentiviral vector with reduced exposure busulfan conditioning.
News
Anti-BCMA CAR T-cell therapy being fast tracked at FDA
The CAR T-cell therapy bb2121 was granted breakthrough therapy designation by the Food and Drug Administration, speeding its review process.
News
Researchers identify potential gene target for AML drug development
Study pinpoints a new mechanism of gene regulation in acute myeloid leukemia.
News
Marginal zone lymphoma treatment studies to be presented at ASH
Several studies will focus on combination treatment approaches in MZL.
News
Mayo experts outline Waldenström macroglobulinemia management
The guidelines are based on studies and expert consensus.
News
Generic clofarabine injection hits the market
The generic is approved for pediatric patients up to 21 years old with relapsed or refractory ALL after two prior regimens.
News
TP53 mutations could help stratify MCL patients
The study looks at response to standard-of-care regimens in younger patients.
News
Lenalidomide shows clinical activity in relapsed/refractory MCL
The observational study highlights the potential of the drug in a population of hard-to-treat patients.
News
AML candidate drug back in the pipeline
Phase 1 trials of UCART123 were halted in September but the FDA has given clearance for research to continue, with conditions.
News
Top research to be presented at AAGL
Dr. Charles E. Miller offers his top picks for research presentations at the 2017 AAGL Global Congress.
News
FDA approves first Erdheim-Chester disease treatment
Vemurafenib is now approved to treat ECD patients with the BRAF V600 mutation.